Caspofungin AcetateThird Party Manufacturing in India

Caspofungin Acetate (CAS 179463-17-3) works by inhibiting the synthesis of beta-(1,3)-D-glucan, an essential polysaccharide component that maintains the structural integrity and rigidity of the fungal cell wall. The molecule selectively targets and blocks the enzyme beta-(1,3)-D-glucan synthase, which is responsible for polymerizing glucose molecules into the glucan fibrils of the cell wall. This specific enzymatic blockade weakens the fungal cell wall, leading to osmotic instability, cellular rupture, and subsequent death of the fungal pathogen. Unlike polyene or azole class antifungals which target cell membrane ergosterol, Caspofungin Acetate directly disrupts cell wall synthesis. Because human cells do not possess a cell wall or express beta-(1,3)-D-glucan synthase, the drug exhibits high selective toxicity toward fungal cells and has a very favorable safety profile in patients. It is highly effective and well-tolerated in adult and pediatric populations who require treatment for systemic fungal infections. The molecule shows broad-spectrum fungicidal activity against Candida species and fungistatic activity against Aspergillus species.

We offer state-of-the-art facilities for Caspofungin Acetate third party manufacturing in India, catering to hospital and intensive care distributors globally. Caspofungin Acetate (CAS 179463-17-3) is an essential echinocandin class antifungal used to treat severe, systemic fungal infections.

Therapeutic Uses

Caspofungin Acetate is indicated for the treatment of:

• Invasive Candidiasis: Used as first-line therapy for systemic Candida infections, including candidemia, peritonitis, intra-abdominal abscesses, and pleural space infections.
• Invasive Aspergillosis: Prescribed for patients who are refractory to or intolerant of other primary antifungal therapies, such as amphotericin B or itraconazole.
• Empiric Therapy for Presumed Fungal Infections: Administered as empirical treatment in febrile, neutropenic patients where a systemic fungal infection is suspected.
• Esophageal Candidiasis: Used to treat severe mucosal Candida infections of the esophagus, especially in immunocompromised patients.

Selecting a Caspofungin Acetate Manufacturer

For critical care distributors, partnering with a reliable Caspofungin Acetate manufacturer ensures a steady supply of life-saving injectables. The synthesis and sterile formulation of echinocandins are complex, requiring advanced lyophilization technology and strict environmental controls.

Our partner production facilities are WHO-GMP certified and utilize aseptic lyophilization systems to produce sterile, high-purity Caspofungin Acetate 50mg and 70mg injections. This WHO-GMP certified sterile dry powder manufacturing ensures excellent stability, meeting international standards. This makes it a highly valuable and high-demand addition to any third party portfolio.